Cited by 2,969Hematopoietic Stem Cell TransplantationInflammatory Biomarkers in Disease PrognosisRenal Transplantation Outcomes and Treatments

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Open access

Sorror, Mohamed L., Maris, Michael B., Storb, Rainer, Baron, Frederic, Sandmaier, Brenda M., Maloney, David G., Storer, Barry·2005·Blood

DOI 10.1182/blood-2005-05-2004PMC PMC1895304

Open this paper in CoChat — free account Open PDF

Abstract

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related comorbidities, and (3) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores more than 0 compared with 12%, respectively. Further, the new index showed better survival prediction than the CCI (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, respectively, P < .001). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT. (Blood. 2005;106: 2912-2919)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-05-2004

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Regression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,804
Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Storb, R. F., Deeg, H. J., Whitehead, J., Appelbaum, F. R., Beatty, P. G., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Farewell, V. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citation
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
McSweeney, P. A., Niederwieser, D. W., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,386
Self-citation

Show all 62 references

Research works printed but not linked: 1

Lubke T, Monig SP, Schneider PM, Holscher AH, Bollschweiler E. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? [German]. Zentralblatt für Chirurgie.2003;128: 970-976.

Sorted by citations

Items 201–300 of 1,002

Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer
Groarke, J. D., Payne, D., Claggett, B. L., Mehra, M. R., Gong, J., Caron, J. P., Mahmood, S., Hainer, J. M., Neilan, T. G., Partridge, A. H., et al. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa015 · Cited by 90
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Roeker, L. E., Dreger, P., Brown, J. R., Lahoud, O. B., Eyre, T. A., Brander, D. M., Skarbnik, A. P. Z., Coombs, C. C., Kim, H. T., Davids, M. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001956 · Cited by 92
Umbilical Cord Blood Transplantation after Reduced-Intensity Conditioning for Elderly Patients with Hematologic Diseases
Uchida, N., Wake, A., Takagi, S., Yamamoto, H., Kato, D., Matsuhashi, Y., Matsumura, T., Seo, S., Matsuno, N., Masuoka, K., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.03.003 · Cited by 90
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Thanarajasingam, G., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Antin, J. H., Soiffer, R. J., & Armand, P. A. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.09.011 · Cited by 90
Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease
Palmer, J. M., Williams, K. M., Inamoto, Y., Chai, X., Martin, P. J., Tomas, L. H. S., Cutler, C. S., Weisdorf, D. J., Kurland, B. F., Carpenter, P. A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.025 · Cited by 91
Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen
Deeg, H. J., Storer, B. E., Boeckh, M., Martin, P. J., McCune, J. S., Myerson, D., Heimfeld, S., Flowers, M. E. D., Anasetti, C., Doney, K., et al. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.12.036 · Cited by 90
Self-citation
Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study
Wood, W. A., Deal, A. M., Reeve, B. B., Abernethy, A. P., Basch, E., Mitchell, S. A., Shatten, C., Kim, Y. H., Whitley, J., Serody, J. S., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.58 · Cited by 89
Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning Intensity
Dietrich, S., Andrulis, M., Hegenbart, U., Schmitt, T., Bellos, F., Martens, U. M., Meißner, J., Krämer, A., Ho, A. D., & Dreger, P. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.12.706 · Cited by 89
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Paras, G., Morsink, L. M., Othus, M. K. D., Milano, F., Sandmaier, B. M., Zarling, L. C., Palmieri, R., Schoch, G. H., Davis, C., Bleakley, M., et al. (2022) · Blood · doi:10.1182/blood.2021014804 · Cited by 88
Self-citation
Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor
Blaise, D., Fürst, S., Crocchiolo, R., Cheikh, J. E., Granata, A., Harbi, S., Bouabdallah, R., Devillier, R., Bramanti, S., Lemarié, C., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.08.029 · Cited by 87
Hematopoietic Cell Transplantation–Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit
Bayraktar, U. D., Shpall, E. J., Liu, P., Ciurea, S. O., Rondón, G., Lima, M. J. G. D., Cárdenas-Turanzas, M., Price, K., Champlin, R. E., & Nates, J. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5867 · Cited by 87
Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit
Halpern, A. B., Culakova, E., Walter, R. B., & Lyman, G. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4858 · Cited by 87
Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study
Kharfan‐Dabaja, M. A., Malki, M. M. A., Deotare, U. R., Raj, R. V., El‐Jurdi, N., Majhail, N. S., Cherry, M. A., Bashir, Q., Darrah, J. M., Nishihori, T., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14954 · Cited by 87
Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center
Guilfoyle, R., Demers, A., Bredeson, C., Richardson, E., Rubinger, M., Szwajcer, D., & Seftel, M. D. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.300 · Cited by 87
Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia
Brunner, A. M., Sadrzadeh, H., Feng, Y., Drapkin, B. J., Ballen, K. K., Attar, E. C., Amrein, P. C., McAfee, S. L., Chen, Y., Neuberg, D. S., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23462 · Cited by 88
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)
Elliot, K., Tooze, J. A., Geller, R. L., Powell, B. L., Pardee, T. S., Ritchie, E. K., Kennedy, L. D., Callahan, K. E., & Klepin, H. D. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.018 · Cited by 87
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
Andersson, B. S., Thall, P. F., Valdez, B. C., Milton, D. R., Alatrash, G., Chen, J., Gulbis, A. M., Chu, D. T., Martinez, C., Parmar, S., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.322 · Cited by 86
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study
Efficace, F., Gaïdano, G., Breccia, M., Voso, M. T., Cottone, F., Angelucci, E., Caocci, G., Stauder, R., Selleslag, D., Sprangers, M. A. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00206-5 · Cited by 86
Acute Myelogenous Leukemia in Older Adults
Klepin, H. D., & Balducci, L. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0224 · Cited by 87
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
Fox, T. A., Chakraverty, R. K., Burns, S. O., Carpenter, B., Thomson, K. J., Lowe, D. M., Fielding, A. K., Peggs, K. S., Kottaridis, P. D., Uttenthal, B. J., et al. (2017) · Blood · doi:10.1182/blood-2017-09-807487 · Cited by 85
Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial
Wang, Y., Liu, Q., Lin, R., Yang, T., Xu, Y., Mo, X., & Huang, X. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.06.002 · Cited by 85
Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation
El-Jawahri, A. R., Traeger, L. N., Kuzmuk, K., Eusebio, J. R., Vandusen, H. B., Keenan, T. E., Shin, J. A., Gallagher, E. R., Greer, J. A., Pirl, W. F., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.113 · Cited by 86
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
Ritgen, M., Böttcher, S., Stilgenbauer, S., Bunjes, D. W., Schubert, J., Cohen, S., Humpe, A., Hallek, M. J., Kneba, M., Schmitz, N., et al. (2008) · Leukemia · doi:10.1038/leu.2008.96 · Cited by 85
Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach
Ananda-Rajah, M. R., Cheng, A., Morrissey, C. O., Spelman, T. D., Dooley, M. J., Neville, A. M., & Slavin, M. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01423-10 · Cited by 85
Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Artz, A. S., Wickrema, A., Dinner, S. N., Godley, L. A., Kocherginsky, M., Odenike, O. M., Rich, E. S., Stock, W., Ulaszek, J., Larson, R. A., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.08.004 · Cited by 85
Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation
Armenian, S. H., Xiao, M., Teh, J. B., Lee, B., Chang, H. A., Mascarenhas, K., Lee, S., Iukuridze, A., Xie, J. J., Scott, J. M., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy231 · Cited by 83
How I treat adult T-cell leukemia/lymphoma
Cook, L. B. M., & Phillips, A. A. (2020) · Blood · doi:10.1182/blood.2019004045 · Cited by 85
Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Brunner, A. M., Kim, H. T., Coughlin, E., Alyea, E. P., Armand, P. A., Ballen, K. K., Cutler, C. S., Dey, B. R., Glotzbecker, B. E., Koreth, J., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.06.008 · Cited by 84
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
Giles, F. J., Rizzieri, D. A., Karp, J. E., Vey, N., Ravandi, F., Faderl, S. H., Khan, K. D., Verhoef, G. E. G., Wijermans, P., Advani, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0961 · Cited by 84
Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT
DeFilipp, Z. M., Duarte, R. F., Snowden, J. A., Majhail, N. S., Greenfield, D., López‐Miranda, J., Arat, M., Baker, K. S., Burns, L. J., Duncan, C., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.203 · Cited by 84
Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation
Tanaka, Y., Kurosawa, S., Tajima, K., Tanaka, T., Ito, R., Inoue, Y., Okinaka, K., Inamoto, Y., Fuji, S., Kim, S.-W., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.330 · Cited by 83
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
Cook, G., Larocca, A., Facon, T. T. F., Zweegman, S., & Engelhardt, M. M. (2020) · Leukemia · doi:10.1038/s41375-020-0918-6 · Cited by 85
Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species
Rolling, T., Zhai, B., Gjonbalaj, M., Tosini, N. L., Yasuma-Mitobe, K., Fontana, E., Amoretti, L. A., Wright, R. J., Ponce, D. M., Perales, M., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00989-7 · Cited by 81
How we approach patient evaluation for hematopoietic stem cell transplantation
Hamadani, M., Craig, M., Awan, F. T., & Devine, S. M. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.94 · Cited by 82
Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation
Hill, J. A., Mayer, B. T., Xie, H., Leisenring, W. M., Huang, M.-L. W., Stevens‐Ayers, T., Milano, F., Delaney, C. S., Jerome, K. R., Zerr, D. M., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix804 · Cited by 83
Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients
Smith, A. R., Majhail, N. S., MacMillan, M. L., DeFor, T. E., Jodele, S., Lehmann, L., Krance, R. A., & Davies, S. M. (2011) · Blood · doi:10.1182/blood-2010-08-303263 · Cited by 82
Acute myeloid leukemia in the elderly: therapeutic options and choice
Webster, J. A., & Pratz, K. W. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1330956 · Cited by 82
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age
Koreth, J., Aldridge, J., Kim, H. T., Alyea, E. P., Cutler, C. S., Armand, P. A., Ritz, J., Antin, J. H., Soiffer, R. J., & Ho, V. T. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.12.537 · Cited by 81
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
Murthy, G. S. G., Kim, S., Hu, Z., Estrada‐Merly, N., Abid, M. B., Aljurf, M. D., Bacher, U., Badawy, S. M., Beitinjaneh, A., Bredeson, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6846 · Cited by 83
Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study
Østgård, L. S. G., Nørgaard, J. M., Sengeløv, H., Severinsen, M. T., Friis, L. S., Marcher, C. W., Dufva, I. H., & Nørgaard, M. (2014) · Leukemia · doi:10.1038/leu.2014.234 · Cited by 81
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313
Pulsipher, M. A., Boucher, K. M., Wall, D. A., Frangoul, H., Duval, M., Goyal, R. K., Shaw, P. J., Haight, A. E., Grimley, M. S., Grupp, S. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-196303 · Cited by 81
Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission
Versluis, J., Labopin, M., Niederwieser, D. W., Socié, G., Schlenk, R. F., Milpied, N. J., Nagler, A., Blaise, D., Rocha, V., Cornelissen, J. J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.164 · Cited by 81
Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation
Vaughn, J. E., Storer, B. E., Armand, P. A., Raimondi, R., Gibson, C. J., Rambaldi, A., Ciceri, F., Oneto, R., Bruno, B., Martin, P. J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.002 · Cited by 80
Self-citation
Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia
Blaise, D., Vey, N., Faucher, C., & Mohty, M. (2007) · Haematologica · doi:10.3324/haematol.10867 · Cited by 80
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
Polverelli, N., Mauff, K. A. L., Kröger, N. M., Robin, M., Beelen, D. W., Beauvais, D., Chevallier, P., Mohty, M., Passweg, J. R., Rubio, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26020 · Cited by 82
Practice variation in physician referral for allogeneic hematopoietic cell transplantation
Pidala, J., Craig, B. M., Lee, S. J., Majhail, N. S., Quinn, G. P., & Anasetti, C. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.95 · Cited by 80
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes
Artz, A. S., Logan, B. R., Zhu, X., Akpek, G., Martino, R., Gupta, V. K., Lazarus, H. M., Litzow, M. R., Loren, A. W., Majhail, N. S., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.145847 · Cited by 80
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide
McCurdy, S. R., Kanakry, C. G., Tsai, H., Kasamon, Y. L., Showel, M. M., Bolaños‐Meade, J., Huff, C. A., Borrello, I., Matsui, W. H., Brodsky, R. A., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.023 · Cited by 79
Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation
Giralt, S., & Bishop, M. R. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_1 · Cited by 90
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
Garderet, L., Beohou, E., Caillot, D., Stoppa, A. M., Touzeau, C., Chrétien, M. L., Karlin, L., Moreau, P., Fontan, J., Blaise, D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.150334 · Cited by 78
Longitudinal follow-up of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation
Urbain, P., Birlinger, J. A., Lambert, C., Finke, J., Bertz, H., & Biesalski, H.-K. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.158 · Cited by 78
Biobehavioral influences on recovery following hematopoietic stem cell transplantation
Costanzo, E. S., Juckett, M., & Coe, C. L. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.07.005 · Cited by 78
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary
Morrison, V. A., Hamlin, P. A., Soubeyran, P., Stauder, R., Wadhwa, P. D., Aapro, M., & Lichtman, S. M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv018 · Cited by 78
Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome
Kleber, M., Ihorst, G., Gross, B. N., Koch, B., Reinhardt, H., Wäsch, R., & Engelhardt, M. M. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.013 · Cited by 78
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT
Robinson, S. P., Canals, C., Luang, J. J., Tilly, H., Crawley, C. R., Cahn, J.-Y. Y., Pohlreich, D., Gouill, S. L., Gilleece, M. H., Milpied, N. J., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.83 · Cited by 77
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome
Silva, L. D. P., Lima, M. J. G. D., Kantarjian, H. M., Faderl, S., Kebriaei, P., Giralt, S., Davisson, J., Garcia‐Manero, G., Champlin, R. E., Issa, J. J., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.400 · Cited by 77
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Abel, G. A., Efficace, F., Buckstein, R. J., Tinsley, S., Jurcic, J. G., Martins, Y., Steensma, D. P., Watts, C. D., Raza, A., Lee, S. J., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140335 · Cited by 72
Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults
Navarro, W. H., Agovi, A. M., Logan, B. R., Ballen, K. K., Bolwell, B. J., Frangoul, H., Gupta, V. K., Hahn, T., Ho, V. T., Juckett, M., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.04.009 · Cited by 77
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality
Pidala, J., Kim, J., Anasetti, C., Nishihori, T., Betts, B. C., Field, T. L., & Perkins, J. B. (2011) · Haematologica · doi:10.3324/haematol.2011.049841 · Cited by 77
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
Pierini, A., Ruggeri, L., Carotti, A., Falzetti, F., Saldi, S., Terenzi, A., Zucchetti, C., Ingrosso, G., Zei, T., Ostini, R. I., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003739 · Cited by 75
Treatment for Relapsed/Refractory Acute Myeloid Leukemia
Thol, F. R., & Heuser, M. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000572 · Cited by 77
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt, M. J., Metheny, L. L., Zhang, M., Wang, H., Estrada‐Merly, N., Marks, D. I., Al‐Homsi, A. S., Muffly, L. S., Chao, N. J. A., Rizzieri, D. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004916 · Cited by 76
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Kerbauy, D. M. B., Chyou, F., Gooley, T. A., Sorror, M. L., Scott, B. L., Pagel, J. M., Myerson, D., Appelbaum, F. R., Storb, R. F., & Deeg, H. J. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.05.008 · Cited by 76
Self-citation
International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome
Dimitrova, D., Nademi, Z., Maccari, M. E., Ehl, S. R., Uzel, G., Tomoda, T., Okano, T., Imai, K., Carpenter, B., Ip, W., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.04.036 · Cited by 75
To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century
Ustun, C., Lazarus, H. M., & Weisdorf, D. J. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.67 · Cited by 75
Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry
Kurosawa, S., Yakushijin, K., Yamaguchi, T., Atsuta, Y., Nagamura‐Inoue, T., Akiyama, H., Taniguchi, S., Miyamura, K., Takahashi, S., Eto, T., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.172 · Cited by 75
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, B. C., Ahn, K. W., Hu, Z., Nishihori, T., Malone, A. K., Valcárcel, D., Grunwald, M. R., Bacher, U., Hamilton, B. K., Kharfan‐Dabaja, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0515 · Cited by 75
Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal
Li, A., Wu, Q. V., Davis, C., Kirtane, K., Pham, P. D., Sorror, M. L., Lee, S. J., Gopal, A. K., Dong, J., Garcia, D. A., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.10.015 · Cited by 75
Self-citation
Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia
Schiller, G. J., O'Brien, S. M., Pigneux, A., DeAngelo, D. J., Vey, N., Kell, J., Solomon, S. R., Stuart, R. K., Karsten, V., Cahill, A. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2008 · Cited by 74
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Lussana, F., Rambaldi, A., Finazzi, M. C., van Biezen, A., Scholten, M., Oldani, E., Carobbio, A., Iacobelli, S., Finke, J., Nagler, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.094284 · Cited by 74
Patient‐reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)
Wood, W. A., Le‐Rademacher, J. G., Syrjala, K. L., Jim, H., Jacobsen, P. B., Knight, J. M., Abidi, M. H., Wingard, J. R., Majhail, N. S., Geller, N. L., et al. (2015) · Cancer · doi:10.1002/cncr.29717 · Cited by 73
Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders
Baron, F., & Storb, R. F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.011 · Cited by 73
Self-citation
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC
Barba, P., Piñana, J. L., Martino, R., Valcárcel, D., Amorós, À., Sureda, A. M., Briones, J., Delgado, J., Brunet, S., & Sierra, J. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.11.008 · Cited by 72
Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI–measured liver iron content
Trottier, B. J., Burns, L. J., DeFor, T. E., Cooley, S., & Majhail, N. S. (2013) · Blood · doi:10.1182/blood-2013-04-499772 · Cited by 72
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives
Sandmaier, B. M., Mackinnon, S., & Childs, R. W. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.10.015 · Cited by 72
Self-citation
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
Elsawy, M., & Sorror, M. L. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.141 · Cited by 72
Self-citation
Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants
Wang, Y., Wu, D., Liu, Q.-F., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Xu, Y. Y., Huang, F., & Huang, X.-J. (2017) · Leukemia · doi:10.1038/leu.2017.199 · Cited by 72
Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR
Sureda, A. M., Zhang, M., Dreger, P., Carreras, J., Fenske, T. S., Finel, H., Schouten, H. C., Montoto, S., Robinson, S. P., Smith, S. M., et al. (2018) · Cancer · doi:10.1002/cncr.31264 · Cited by 72
Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning
Reshef, R., Hexner, E. O., Loren, A. W., Frey, N. V., Stadtmauer, E. A., Luger, S. M., Mangan, J. K., Gill, S. I., Vassilev, P., Lafferty, K. A., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.003 · Cited by 71
Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients
Loggers, E. T., LeBlanc, T. W., El-Jawahri, A. R., Fihn, J., Bumpus, M., David, J. H., Horak, P., & Lee, S. J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.03.006 · Cited by 73
Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study
Andria, N., Henig, O., Kotler, O., Domchenko, A., Oren, I., Zuckerman, T., Ofran, Y., Fraser, D., & Paul, M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv218 · Cited by 71
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes
Efficace, F., Gaïdano, G., Breccia, M., Criscuolo, M., Cottone, F., Caocci, G., Bowen, D., Lübbert, M., Angelucci, E., Stauder, R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13138 · Cited by 71
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
Kleber, M., Ihorst, G., Deschler-Baier, B., Jakob, C., Liebisch, P., Koch, B., Sezer, O., & Engelhardt, M. M. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01318.x · Cited by 71
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Beelen, D. W., Stelljes, M., Reményi, P., Wagner‐Drouet, E., Dreger, P., Bethge, W. A., Ciceri, F., Stölzel, F., Junghanß, C., Labussière‐Wallet, H., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26620 · Cited by 70
Arrhythmias in the setting of hematopoietic cell transplants
Tonorezos, E. S., Stillwell, E. E., Calloway, J. J., Glew, T., Wessler, J. D., Rebolledo, B. J., Pham, A., Steingart, R. M., Lazarus, H. M., Gale, R. P., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.127 · Cited by 70
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery
Dodero, A., Carniti, C., Raganato, A., Vendramin, A., Farina, L., Spina, F., Carlo‐Stella, C., Terlizzi, S. D., Milanesi, M., Longoni, P. D., et al. (2009) · Blood · doi:10.1182/blood-2008-10-183723 · Cited by 70
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Robinson, S. P., Dreger, P., Caballero, D. M., Corradini, P., Geisler, C., Ghielmini, M. E. G., Gouill, S. L., Kimby, E. K., Rule, S. A., Vitolo, U., et al. (2014) · Leukemia · doi:10.1038/leu.2014.223 · Cited by 70
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mawad, R., Gooley, T. A., Rajendran, J. G., Fisher, D. R., Gopal, A. K., Shields, A. T., Sandmaier, B. M., Sorror, M. L., Deeg, H. J., Storb, R. F., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.014 · Cited by 70
Self-citation
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
Breccia, M., Latagliata, R., Stagno, F., Luciano, L., Gozzini, A., Castagnetti, F., Fava, C., Cavazzini, F., Annunziata, M., Rossi, A. R., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.041251 · Cited by 70
Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I
McCune, J. S., & Bemer, M. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0339-2 · Cited by 70
Toward a pathophysiology inspired treatment of VEXAS syndrome
Heiblig, M., Patel, B. A., Groarke, E. M., Bourbon, E., & Sujobert, P. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.09.001 · Cited by 71
A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia
Terwey, T. H., Hemmati, P., Martus, P., Dietz, E., Vuong, L. G., Massenkeil, G., Dörken, B., & Arnold, R. (2009) · Haematologica · doi:10.3324/haematol.2009.011809 · Cited by 69
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies
Yamamoto, H., Uchida, N., Yuasa, M., Kageyama, K., Ota, H., Kaji, D., Nishida, A., Ishiwata, K., Takagi, S., Tsuji, M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.017 · Cited by 69
Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation
Sugita, J., Kamimura, T., Ishikawa, T., Ota, S., Eto, T., Kuroha, T., Miyazaki, Y., Kumagai, H., Matsuo, K., Akashi, K., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01065-0 · Cited by 68
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies
Duléry, R., Goudet, C., Mannina, D., Bianchessi, A., Granata, A., Harbi, S., Maisano, V., Chabannon, C., Malard, F., Brissot, É., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01908-y · Cited by 68
Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment
Sénesse, P., Bachmann, P., Bensadoun, R., Besnard, I., Bourdel‐Marchasson, I., Bouteloup, C., Crenn, P. P., Goldwasser, F., Guérin, O., Latino‐Martel, P., et al. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.01.160 · Cited by 68
Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical Cord Blood and Matched Related Donor Transplants
Majhail, N. S., Brunstein, C. G., McAvoy, S., DeFor, T. E., Al-Hazzouri, A., Setubal, D. C., Arora, M., Le, C. T., Wagner, J. E., & Weisdorf, D. J. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.06.008 · Cited by 68
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 67
Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients
Wils, E., van der Holt, B., Broers, A. E. C., Sluijs, S. J. P.-V., Gratama, J. W., Braakman, E., & Cornelissen, J. J. (2011) · Haematologica · doi:10.3324/haematol.2011.047696 · Cited by 69
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
Choi, S. W., Braun, T., Henig, I. J., Gatza, E., Magenau, J. M., Parkin, B. L., Pawarode, A., Riwes, M. M., Yanik, G. A., Dinarello, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-06-790469 · Cited by 68

Authors: Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B.
Affiliations: University of Washington (US)
From the Fred Hutchinson Cancer Research Center, Seattle, WA; and the University of Washington, Seattle, WA.
ORCID: Sorror, Mohamed L.
Storb, Rainer
Sandmaier, Brenda M.
Maloney, David G.
Storer, Barry
Venue: Blood
Publisher: American Society of Hematology
Published: 2005-10-15
Volume: 106
Issue: 8
Pages: 2912-2919
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-05-2004
PMC: PMC1895304
OpenAlex: W2128812336
Cited by: 2,969
References: 62
Citations by year: 2026: 139 · 2025: 208 · 2024: 223 · 2023: 213 · 2022: 192 · 2021: 246 · 2020: 209 · 2019: 171 · 2018: 173 · 2017: 174 · 2016: 144 · 2015: 145 · 2014: 134 · 2013: 112 · 2012: 86
FWCI: 25.46
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Funders: Fred Hutchinson Cancer Research Center
University of Washington
National Heart, Lung, and Blood Institute (HL-36444, P01HL036444)
National Cancer Institute (CA 49605, CA18029, CA 15704+, K23CA092058, CA 78902, CA92058, P01CA049605, P30CA015704, P01CA018029, P01CA078902)
Topics: Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Keywords: hematopoietic stem cell transplantation, allogeneic transplantation, comorbidity index, Charlson Comorbidity Index, risk assessment, non-relapse mortality, survival prediction, prognostic scoring
MeSH terms: Contraindications, Adolescent, Adult, Aged, Cause of Death, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Prognosis, Transplantation, Homologous, Reproducibility of Results, Comorbidity, Survival Rate, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks